EUVIMEDSkopri EUVIMED
Crossref

Ketamine shows long‐term benefit in patients with treatment‐resistant depression

The Brown University Psychopharmacology Update · 2026-05 · 37 (5) · 3-3

DOI: 10.1002/pu.31440 ↗

At a glance

Journal article in The Brown University Psychopharmacology Update, published online on 2026-04-08.

AstrattDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Patients with treatment‐resistant depression who received a series of treatments with ketamine or esketamine showed a substantial reduction in emergency department visits related to suicidality over a 6‐month period, a study has found. Study participants had a 56.7% response rate of depression symptoms following the acute phase of treatment.

Cite

APA

(2026). Ketamine shows long‐term benefit in patients with treatment‐resistant depression. The Brown University Psychopharmacology Update, 37(5), 3-3. https://doi.org/10.1002/pu.31440

Vancouver

Ketamine shows long‐term benefit in patients with treatment‐resistant depression. The Brown University Psychopharmacology Update. 2026;37(5):3-3. doi:10.1002/pu.31440

BibTeX
@article{euvimed2026,
  title = {Ketamine shows long‐term benefit in patients with treatment‐resistant depression},
  journal = {The Brown University Psychopharmacology Update},
  year = {2026},
  volume = {37},
  number = {5},
  pages = {3--3},
  doi = {10.1002/pu.31440}
}
Start for free →